XORTX Therapeutics Boosts Board with Biotech Pro
Company Announcements

XORTX Therapeutics Boosts Board with Biotech Pro

Xortx Therapeutics (TSE:XRTX) has released an update.

XORTX Therapeutics has announced the addition of biotech veteran Abigail Jenkins to its Board of Directors, who brings over two decades of experience in commercializing renal and cardiovascular therapies. Jenkins’ extensive background in guiding drugs from research to market is expected to greatly benefit XORTX as they transition towards the commercialization phase for their advanced clinical products. The company, specializing in treatments for progressive kidney disease, has granted Jenkins stock options as part of her appointment.

For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskXORTX Outlines Executive Compensation Strategy
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Plans Major Warrant Repricing
TipRanks Auto-Generated NewsdeskXORTX Therapeutics Showcases Progress at BIO 2024
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!